Global Medical REIT Inc. (NYSE: GMRE) — Q2 2021 Form 10-Q
Issuer clarification: The request metadata names Chiron Real Estate Inc., but the supplied filing is for Global Medical REIT Inc. This summary covers Global Medical REIT’s unaudited quarter and six months ended June 30, 2021; comparative figures are for 2020 unless stated otherwise. Amounts are in U.S. dollars.
Business context
Global Medical REIT acquires purpose-built healthcare facilities and leases them to healthcare systems and physician groups. At June 30, 2021, its portfolio comprised 97 facilities and approximately 4.05 million leasable square feet. The company completed 11 acquisitions during the first half for an aggregate contractual purchase price of $113.8 million.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenue | $28.3 million | $22.1 million | $55.6 million | $43.7 million |
| Net income | $4.2 million | $1.7 million | $7.5 million | $4.5 million |
| Net income attributable to common stockholders | $2.6 million | $0.2 million | $4.3 million | $1.5 million |
| Basic and diluted common EPS | $0.04 | $0.00 | $0.08 | $0.03 |
| FFO per share and unit | $0.22 | $0.19 | $0.44 | $0.38 |
| AFFO per share and unit | $0.23 | $0.21 | $0.47 | $0.41 |
| Common dividend per share | $0.205 | $0.20 | $0.41 | $0.40 |
GAAP net income margin was approximately 14.7% for Q2 2021 versus 7.6% in Q2 2020, and 13.5% for the first half versus 10.3%. These calculations use reported net income divided by total revenue. FFO and AFFO are non-GAAP measures; the company’s definitions and reconciliations appear in the filing.
- Cash flow: First-half operating cash flow was $33.1 million, up from $23.9 million. Investing used $116.0 million, mainly for property acquisitions; financing provided $84.5 million, including equity proceeds. Cash and restricted cash ended the period at $12.4 million.
- Assets and equity: Total assets were $1.200 billion, including net real estate of $1.143 billion. Total equity, including noncontrolling interests, was $637.3 million.
- Debt and liquidity: Net debt was $506.8 million, down from $586.6 million at year-end 2020. The weighted-average debt rate was 3.09%, with a weighted-average term of 4.71 years. As of August 2, the company reported approximately $265 million of unused revolver capacity.
- Dividends: First-half common dividends were $0.41 per share; preferred dividends were $2.9 million. Common AFFO per share and unit exceeded the declared common dividend per share for the period, but that comparison is not a cash-flow or dividend-safety guarantee.
Material changes versus the prior period
- Q2 revenue increased 28% and first-half revenue increased 27%, largely from facilities acquired since the comparable 2020 periods and fuller-period contributions from earlier acquisitions. First-half net income rose to $7.5 million from $4.5 million.
- Portfolio growth increased depreciation, amortization, and operating expenses. G&A also rose substantially, partly because costs previously borne by the external advisor became company expenses after the July 2020 management internalization. Related-party management fees and internalization expense were absent in 2021.
- Common shares outstanding increased to 64.2 million from 49.5 million at year-end 2020. First-half equity proceeds included $109.6 million net from a public offering and $85.3 million net from ATM issuances. The larger share count is relevant when assessing per-share growth.
- The May 2021 amended credit facility increased capacity from $600 million to $750 million, changed it from secured to unsecured, and extended maturities: the revolver to May 2025 and term loan to May 2026, subject to stated extension options.
Outlook, risks, and unusual items
- The filing gives no numerical earnings or acquisition guidance. Management cited expected long-term support from healthcare spending, an aging population, outpatient-care growth, and provider consolidation, while noting stronger competition for healthcare properties may pressure acquisition returns.
- Management reported no material COVID-19 impact on the business during the periods presented, but warned that renewed outbreaks or variants could impair tenants’ ability to pay rent, financing access, or equity issuance.
- Other risks include tenant defaults or non-renewals, rent collection, healthcare reimbursement changes, acquisition execution, interest-rate exposure, covenant compliance, and the transition away from LIBOR. The company reported $101.1 million of unhedged floating-rate borrowings; a 100-basis-point LIBOR increase was estimated to reduce annual cash flow by about $1.0 million, assuming debt levels were unchanged.
- Interest-rate swaps hedge the $350 million term loan, but their net fair-value liability was $13.7 million at quarter-end. The company estimated $6.2 million would be reclassified as an increase to interest expense over the next 12 months.
- Capital-improvement commitments were approximately $28.4 million; obligations over the next 12 months could reach approximately $18.0 million. The company also identified a near-term debt maturity of $7.0 million.
- Subsequent to quarter-end, the company completed two acquisitions for $26.2 million and had three properties under contract for approximately $23.2 million, subject to due diligence. Management reported covenant compliance as of August 2. No material litigation or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Confirm the issuer identity: this supplied filing is Global Medical REIT Inc., not Chiron Real Estate Inc.
- Review tenant credit quality, rent collections, lease expirations, and acquisition economics; growth in reported revenue primarily reflects portfolio expansion.
- Assess dilution from public and ATM share issuances alongside per-share FFO, AFFO, and dividend trends.
- Review debt covenants, upcoming maturities, available revolver capacity, and LIBOR-to-SOFR transition terms, including hedge coverage and swap exposure.
- Evaluate liquidity after planned acquisitions, dividends, debt service, and capital-improvement commitments; reported cash and restricted cash totaled $12.4 million.